Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kestra Medical TechnologiesKMTS -2.34%10 FCF Yield % is -8.52 as of Jul. 15, 2026. GuruFocus rates KMTS with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Kestra Medical Technologies ranks worse than 71.46% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Kestra Medical Technologies FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Kestra Medical Technologies FCF Yield % Related Terms
Kestra Medical Technologies FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Kestra Medical Technologies's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kestra Medical Technologies FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kestra Medical Technologies's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Kestra Medical Technologies's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kestra Medical Technologies (KMTS) has a FCF Yield % of -8.52 as of Jul. 15, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Kestra Medical Technologies and its competitors. According to the industry distribution chart, Kestra Medical Technologies ranks #611 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 71.5%.
Is Kestra Medical Technologies' FCF Yield % too high?
Kestra Medical Technologies' current FCF Yield % is -8.52. Based on the distribution chart, Kestra Medical Technologies ranks #611 out of 855 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Kestra Medical Technologies has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' FCF Yield % compare to ATRC and STAA?
According to the Medical Devices & Instruments industry distribution chart, Kestra Medical Technologies ranks #611 out of 855 companies for FCF Yield %. This places Kestra Medical Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Kestra Medical Technologies and its competitors. Kestra Medical Technologies's current FCF Yield % is -8.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current FCF Yield % of -8.52. The current FCF Yield % is -8.52. Kestra Medical Technologies' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current FCF Yield % is -8.52 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
10GF Score
Get the complete analysis for KMTS
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KMTS has been successfully added to your 
